About Lodo Therapeutics
Lodo Therapeutics is a company based in New York (United States) founded in 2015 by Sean Brady was acquired by Zymergen in May 2021.. Lodo Therapeutics has raised $19.87 million across 1 funding round from investors including AbbVie, Lilly and ARE. The company has 24 employees as of December 31, 2022. Lodo Therapeutics has completed 2 acquisitions, including Conifer Point and Hibiskus. Lodo Therapeutics offers products and services including AI Models, Data Generation, and Lab Automation. Lodo Therapeutics operates in a competitive market with competitors including Insmed, Affinivax, Eligo Bioscience, Symbiomix Therapeutics and SpyBiotech, among others.
- Headquarter New York, United States
- Employees 24 as on 31 Dec, 2022
- Founders Sean Brady
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Lodo Therapeutics Corporation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$19.87 M (USD)
in 1 rounds
-
Latest Funding Round
$19.87 M (USD), Series A
Jan 04, 2017
-
Investors
AbbVie
& 13 more
-
Employee Count
24
as on Dec 31, 2022
-
Investments & Acquisitions
Conifer Point
& 1 more
-
Acquired by
Zymergen
(May 28, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lodo Therapeutics
Lodo Therapeutics offers a comprehensive portfolio of products and services, including AI Models, Data Generation, and Lab Automation. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides fine-tuning for AI in biotechnology research
Generates high-quality datasets for R&D applications
Offers hardware and software for efficient lab processes
Unlock access to complete
Unlock access to complete
Leadership Team
9 people
Product Management Team
1 people
Finance and Accounting
1 people
CTO Team
1 people
Unlock access to complete
Funding Insights of Lodo Therapeutics
Lodo Therapeutics has successfully raised a total of $19.87M through 1 strategic funding round. The most recent funding activity was a Series A round of $19.87 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $19.9M
-
First Round
First Round
(04 Jan 2017)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2017 | Amount | Series A - Lodo Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Lodo Therapeutics
Lodo Therapeutics has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include AbbVie, Lilly and ARE. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Economic growth is supported via family-backed investments in New York.
|
Founded Year | Domain | Location | |
|
VC firm funding companies in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Lodo Therapeutics
Lodo Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Conifer Point and Hibiskus. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small-molecule therapeutics for cancer are developed by Hibiskus.
|
2017 | ||||
|
New drugs are developed using custom fragment-based design software.
|
2015 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Lodo Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lodo Therapeutics Comparisons
Competitors of Lodo Therapeutics
Lodo Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Eligo Bioscience, Symbiomix Therapeutics and SpyBiotech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small molecule inhibitors for rare lung diseases
|
|
| domain | founded_year | HQ Location |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| domain | founded_year | HQ Location |
Late-stage biopharma antibiotics for gynecological infections are developed.
|
|
| domain | founded_year | HQ Location |
Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lodo Therapeutics
Frequently Asked Questions about Lodo Therapeutics
When was Lodo Therapeutics founded?
Lodo Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is Lodo Therapeutics located?
Lodo Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Is Lodo Therapeutics a funded company?
Lodo Therapeutics is a funded company, having raised a total of $19.87M across 1 funding round to date. The company's 1st funding round was a Series A of $19.87M, raised on Jan 04, 2017.
How many employees does Lodo Therapeutics have?
As of Dec 31, 2022, the latest employee count at Lodo Therapeutics is 24.
What does Lodo Therapeutics do?
Lodo Therapeutics was founded in 2015 and is based in New York, United States. Operations center on the biotech sector, where a metagenomics-driven platform is employed for discovering, biosynthesizing, and characterizing genetically encoded small molecules from microbial sources. Microbiome-derived pharmaceutical products are identified, with a focus on treatments for resistant infectious diseases, cancers, and tuberculosis.
Who are the top competitors of Lodo Therapeutics?
Lodo Therapeutics's top competitors include Insmed, MaaT Pharma and Basilea.
What products or services does Lodo Therapeutics offer?
Lodo Therapeutics offers AI Models, Data Generation, and Lab Automation.
How many acquisitions has Lodo Therapeutics made?
Lodo Therapeutics has made 2 acquisitions, including Conifer Point, and Hibiskus.
Who are Lodo Therapeutics's investors?
Lodo Therapeutics has 14 investors. Key investors include AbbVie, Lilly, ARE, New York State, and Zymergen.